Episodes
Thursday Sep 15, 2016
HIP-HIP-HOPE-3! Expanded role for statin therapy for primary prevention
Thursday Sep 15, 2016
Thursday Sep 15, 2016
The HOPE-3 trial sought to determine if blood pressure (BP) and cholesterol-lowering therapies are effective and safe as primary prevention strategies in intermediate risk patients. The American College of Cardiology and American Heart Association (ACC/AHA) guidelines support a risk-based approach to statin use but in intermediate risk patients the tradeoffs between benefit and risk were deemed “less clear.” Do the results of HOPE-3 trial provide enough evidence to support routinely treating intermediate risk patients?
Saturday Sep 05, 2015
PCSK9 Inhibitors: Blockbusters or Bust?
Saturday Sep 05, 2015
Saturday Sep 05, 2015
Two new mAbs, alirocumab and evolocumab, have been approved to treat elevated cholesterol when added to maximally tolerated statin therapy in patients with familial hypercholesterolemia or history of atherosclerotic cardiovascular disease (ASCVD). This new class of drugs, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, is considered to be the biggest breakthrough in cholesterol treatment since statins were approved 3 decades ago. But are they worth it?
Tuesday Jul 28, 2015
CVD Risk Scores - Are They Accurate?
Tuesday Jul 28, 2015
Tuesday Jul 28, 2015
How well do cardiovascular disease risk calculators really perform? Do they over or underestimate risk? Should we rely on them to make treatment decisions?
Monday Feb 16, 2015
Potential Uses of Niacin: Flushing Out The Results of HPS2-THRIVE
Monday Feb 16, 2015
Monday Feb 16, 2015
Guidelines promote the use of statins as first line therapy to prevent atherosclerotic cardiovascular disease events. Does adding niacin to statin treatment reduce residual risk?